Joint (NASDAQ:JYNT) PT Raised to $32.00

Joint (NASDAQ:JYNT) had its price target increased by stock analysts at DA Davidson to $32.00 in a research note issued to investors on Tuesday, The Fly reports. The brokerage presently has a “buy” rating on the stock. DA Davidson’s target price would suggest a potential upside of 73.72% from the company’s previous close.

Other research analysts have also recently issued reports about the stock. Lake Street Capital increased their price objective on shares of Joint from $20.00 to $30.00 and gave the company a “buy” rating in a report on Friday, August 9th. B. Riley set a $23.00 price objective on shares of Joint and gave the company a “buy” rating in a report on Friday, August 9th. BidaskClub upgraded shares of Joint from a “buy” rating to a “strong-buy” rating in a report on Thursday, September 19th. TheStreet cut shares of Joint from a “b-” rating to a “c” rating in a report on Tuesday, September 3rd. Finally, Maxim Group restated a “buy” rating and set a $25.00 target price on shares of Joint in a report on Friday. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $26.00.

NASDAQ JYNT traded up $0.14 on Tuesday, hitting $18.42. The stock had a trading volume of 568 shares, compared to its average volume of 141,442. Joint has a one year low of $6.51 and a one year high of $21.80. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 3.33. The stock has a market cap of $265.11 million, a price-to-earnings ratio of 460.50 and a beta of 1.01. The company’s 50-day moving average is $18.82 and its two-hundred day moving average is $18.11.

Joint (NASDAQ:JYNT) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.01. The business had revenue of $12.73 million during the quarter, compared to analysts’ expectations of $11.60 million. Joint had a net margin of 6.57% and a return on equity of 120.03%. On average, sell-side analysts anticipate that Joint will post 0.2 earnings per share for the current year.

Several large investors have recently modified their holdings of JYNT. Marshall Wace North America L.P. bought a new position in Joint in the 1st quarter worth about $47,000. Strs Ohio bought a new position in Joint in the 2nd quarter worth about $63,000. Skylands Capital LLC grew its position in Joint by 4.4% in the 2nd quarter. Skylands Capital LLC now owns 550,701 shares of the company’s stock worth $10,023,000 after purchasing an additional 23,051 shares during the last quarter. Wedge Capital Management L L P NC bought a new position in Joint in the 2nd quarter worth about $719,000. Finally, Wells Fargo & Company MN bought a new position in Joint in the 2nd quarter worth about $227,000. Institutional investors and hedge funds own 64.80% of the company’s stock.

Joint Company Profile

The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of March 07, 2019, the company operated 450 clinics in the United States.

See Also: Recession

The Fly

Analyst Recommendations for Joint (NASDAQ:JYNT)

Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter.